Startseite>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Isosilybin A

Isosilybin A

Katalog-Nr.GC36343

Isosilybin A, ein aus Silymarin isoliertes Flavonolignan, wirkt gegen Prostatakrebs (PCA). Isosilybin A hemmt die Proliferation und induziert G1-Phasenarrest und Apoptose in Krebszellen, was die apoptotische Maschinerie in PCA-Zellen aktiviert, indem es auf die Achse des Akt-NF-κB-Androgenrezeptors (AR) abzielt.

Products are for research use only. Not for human use. We do not sell to patients.

Isosilybin A Chemische Struktur

Cas No.: 142796-21-2

Größe Preis Lagerbestand Menge
1mg
185,00 $
Auf Lager
5mg
324,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis[1][2].

[1]. Deep G, et al. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostatecancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul;28(7):1533-42. [2]. Deep G, et al. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling. Mol Carcinog. 2010 Oct;49(10):902-12.

Bewertungen

Review for Isosilybin A

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Isosilybin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.